Business Wire

NIPPON-SHOKUBAI

20.9.2022 15:31:37 CEST | Business Wire | Press release

Share
NIPPON SHOKUBAI: Investment in a Manufacturer of Lithium Salt as the Electrolyte for Lithium-ion Battery in China

NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter “Nippon Shokubai”) (TOKYO:4114) aims to expand our LiFSI* business in China, the biggest market of lithium-ion batteries (hereinafter “LIB”). We hereby announce that, as part of this business expansion, we have reached agreement on investment in Hunan Fluopont New Materials Co., Ltd. (hereinafter “Hunan Fluopont”), a subsidiary of Shenzhen CAPCHEM Technology Co. Ltd. (hereinafter “Capchem”), who is currently making efforts to establish production facilities to enter LiFSI business.
*Lithium bis (fluorosulfonyl) imide (Product name: IONEL™), a lithium salt as the advanced electrolyte which was commercialized first in the world by Nippon Shokubai.

1. Background of the alliance

With a rising awareness of environmental issues in recent years, there is a high demand for electric vehicle (EV), which is an industry-leading product of energy-saving and low-pollution next-generation vehicles, and this has led to the rapid expansion of the LIB market for EV. Because using LiFSI as an electrolyte in LIB for EV significantly improves the battery’s cyclic and rate performance as well as storing stability over a wide temperature range from low to high temperatures, LiFSI has been adapted not only as an additive, but also as a main ingredient of the electrolyte. As this has led to a surge in LiFSI demand particularly in Asia and Europe, early business expansion to China, the world’s biggest LIB market for vehicles has been a key for us to make a big leap in our IONEL™ business.

2. Purpose of the alliance

Under these circumstances, in order to acquire high-profile customers and early establish a cost-competitive manufacturing and sales structure in China with the largest LIB demand, we have decided to form an alliance with Capchem, a major electrolyte solution manufacturer, and Toyota Tsusho Corporation (Headquarters: Nagoya, Japan, President: Ichiro Kashitani, hereinafter “Toyota Tsusho”), who is Toyota Group’s general trading company. The investment will be made by Toyota Tsusho (Shanghai) Co., Ltd. (hereinafter “Toyotsu Shanghai”). This will allow us to combine our state-of-the-art LiFSI production technologies, quality control capability, and intellectual properties with Hunan Fluopont’s cost-competitiveness, location, material procurement capability, production system, and existing technologies, and Capchem’s LiFSI purchasing capability supported by their top-level supply capacity of electrolyte solutions, as well as Toyota Tsusho’s world-wide sales network encompassing China. Through this alliance, we will aim to accelerate our IONEL™ business in the electrolyte market.

LiFSI is known as a difficult substance to purify to a high degree, which is only achieved by advanced know-how for its production and quality management. Using our unique production technology that we have nurtured over the years, in 2013, we succeeded in the development of an industrial production process of highly-pure LiFSI with few solvents and by-products, exhibiting stable electrochemical properties, for the first time in the world. Our product has been adopted and certified as the electrolyte by many LIB manufacturers inside and outside Japan with a wide variety of applications including vehicle, consumer-use, and stationary batteries.
(For details of LiFSI, please refer to our website: https://www.shokubai.co.jp/en/lp/ionel/)

Capchem is the world’s second largest manufacturer of electrolyte solution for LIB with five production sites in China, and has a track record of providing its products to major LIB manufacturers. Their business includes not only manufacturing of electrolyte solution, but also in-house material production of solvent, electrolyte, additive, which enables them to offer electrolyte solution with price competitiveness and high quality.

Toyota Tsusho is looking to expand their LiFSI sales beyond China to electrolyte solution manufactures in Japan, Asia, and Europe to meet the surging demand in the electrolyte solution and electrolyte markets.

Hunan Fluopont started its production in the second half of FY2022 with the first unit (production capacity 1,200t/y). It is planned to be expanded in stages to satisfy the rapidly increasing market demand, aiming to have annual production capacity of 12,000 ton/y in 2025.

3. Investment overview

Nippon Shokubai and Toyotsu Shanghai will invest in the following company.

(1)

 

Company name

 

 

Hunan Fluopont New Materials Co., Ltd.

(2)

 

Location

 

 

Shigu District, Hengyang, Hunan, China

(3)

 

Amount invested (third-party allocation of shares)

 

 

Nippon Shokubai: 201,769,912 RMB (4.04 billion JPY)

 

 

Toyotsu Shanghai: 29,203,539 renminbi (580 million JPY)

 

 

[Assumed exchange rate: 20 JPY/RMB]

(4)

 

Shareholders

 

 

Capchem: 51.19%

 

 

Nippon Shokubai: 38.0%

 

 

Toyotsu Shanghai: 5.5%

 

 

Changsha ShinLian Huayuan Alternative Energy Partnership Enterprise (shareholding association by executive employees of Hunan Fluopont): 5.31%

(5)

 

Representative

 

 

Shu Ping Ai

(6)

 

Businesses

 

 

Manufacturing and sales of electrolyte LiFSI for LIB

(7)

 

Production capacity

 

 

Current: 1,200t/year in the second half of FY2022

 

 

Plan: 12,000t/year in FY2025

Related information

Profile of Shenzhen CAPCHEM Technology Co. Ltd.

Company Name

Shenzhen CAPCHEM Technology Co. Ltd.

Location

Capchem Plaza, Changye Road, Pingshan District, Shenzhen, Guangdong Province, China.

Establishment

1996

Capital

410 million RMB (8.2 billion JPY) (as of end of 2021)

Total assets

223.3 billion JPY (as of end of 2021)

Sales

139 billion JPY (FY2021)

Operating profit

30.8 billion JPY (FY2021)

Business overview

Lithium battery chemicals, organic fluorine chemicals, capacitor chemicals and semiconductor chemicals. For lithium-ion battery electrolytes in mass production at five production sites in China and several other production sites under construction in China and Poland.

Website

https://en.capchem.com/

Profile of Toyota Tsusho Corporation

Company Name

Toyota Tsusho Corporation

Location

9-8, Meieki 4-chome, Nakamura-ku, Nagoya 450-8575 Japan

Establishment

1948

Capital

64.9 billion yen (as of end of March 2022)

Total assets

6,143.1 billion yen (as of end of March 2022)

Sales

8,028 billion yen (FY 2021)

Operating profit

294.1 billion yen (FY 2021)

Business overview

As a general trading company of Toyota Group, the company has expanded its business with a focus on exports of vehicles and automobile production support. The company has seven business fields (Metals, Global Parts & Logistics, Automotive, Machinery, Energy & Project , Chemicals & Electronics, , Food & Consumer Services, and Africa). and focuses on three core businesses, Mobility business that contributes to future convenient society, Resources & Environment business that contributes to sustainable society and Life & Community business that contributes to comfortable & healthy society. Around 65,000 Group employees are engaged in business in about 130 countries.

Website

https://www.toyota-tsusho.com/english/

Profile of Toyotsu Shanghai

Company Name

TOYOTA TSUSHO (SHANGHAI) CO.,LTD.

Location

1717 Nanjing West Road, Jinganqu, Shanghai, China

Establishment

1995

Capital

33.18 million RMB (660 million JPY) (as of end of March 2022)

Business overview

The company mainly operates trading businesses with a wide variety of business units including Metal, Global and Logistics, Chemical Products and Electronics, Mechanical and Energy Plant Project, Food and Household Items, and East Asia Next Mobility Promotion Project.

About NIPPON SHOKUBAI: Since 1941, Nippon Shokubai has grown up its business with unique catalyst technology. Nippon Shokubai has supplied, for example, ethylene oxide and acrylic acid. Among all, our production capacity of superabsorbent polymers is the largest in the world (according to Nippon Shokubai research). We are currently focused on the Solutions Business, and IONEL (LiFSI) mentioned on this announcement plays a key role in accelerating the business. Nippon Shokubai is a global chemical company operating under its corporate mission “TechnoAmenity - Providing prosperity and comfort to people and society, with our unique technology.”
https://www.shokubai.co.jp/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908006154/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin

Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release

Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer

TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the

Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse

Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste

Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye